Literature DB >> 29161150

Cognitive impairment in schizophrenia and depression: A comparison of stability and course.

Peter Neu1,2, Tina Gooren1, Ulrike Niebuhr3, Peter Schlattmann4.   

Abstract

Cognitive deficits are clinically relevant features in schizophrenia and depression, yet little comparative data on changes in both disorders is available. This study compares cognitive performance of inpatients with schizophrenia (N = 52) and unipolar major depression (N = 67) during psychiatric treatment, assessing performance twice: after admission to hospital (acute) and prior to discharge (postacute) on average seven weeks later. A group of healthy controls was tested at comparable intervals. Data was analyzed using a multivariate linear model. Patients with schizophrenia and depression showed significantly impaired performance compared to healthy controls. On follow-up both patient groups showed improved performance. Contrary to expectation, patients with schizophrenia showed greater improvement in verbal memory, visual memory, and psychomotor speed than depressive patients. Verbal fluency presented as a possible candidate to differentiate between both disorders. Similar profiles of generalized cognitive deficits were observed in both patient-groups on acute and postacute assessment, which might indicate trait-like deficits with persistent functional implications in both disorders. Findings do not support assumptions of greater cognitive impairment in schizophrenia compared to depression. A distinction of the disorders on the grounds of cognitive functioning seems to be less specific than presumed.

Entities:  

Keywords:  Acute; cognitive impairment; depression; postacute; schizophrenia; time-course

Mesh:

Year:  2017        PMID: 29161150     DOI: 10.1080/23279095.2017.1392962

Source DB:  PubMed          Journal:  Appl Neuropsychol Adult        ISSN: 2327-9095            Impact factor:   2.248


  5 in total

1.  Early childhood depression, emotion regulation, episodic memory, and hippocampal development.

Authors:  Deanna M Barch; Michael P Harms; Rebecca Tillman; Elizabeth Hawkey; Joan L Luby
Journal:  J Abnorm Psychol       Date:  2019-01

2.  One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia.

Authors:  Luyao Xia; Lei Liu; Xiaohong Hong; Dongmei Wang; Gaoxia Wei; Jiesi Wang; Huixia Zhou; Hang Xu; Yang Tian; Qilong Dai; Hanjing E Wu; Catherine Chang; Li Wang; Thomas R Kosten; Xiang Yang Zhang
Journal:  Neuropsychopharmacology       Date:  2020-04-29       Impact factor: 7.853

3.  Therapeutic Potential of Curcumin in Reversing the Depression and Associated Pseudodementia via Modulating Stress Hormone, Hippocampal Neurotransmitters, and BDNF Levels in Rats.

Authors:  Asia Afzal; Zehra Batool; Sadia Sadir; Laraib Liaquat; Sidrah Shahzad; Saiqa Tabassum; Saara Ahmad; Noor Kamil; Tahira Perveen; Saida Haider
Journal:  Neurochem Res       Date:  2021-08-18       Impact factor: 3.996

Review 4.  Neurocognitive deficits in depression: a systematic review of cognitive impairment in the acute and remitted state.

Authors:  Dominik Kriesche; Christian F J Woll; Nadja Tschentscher; Rolf R Engel; Susanne Karch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-09-01       Impact factor: 5.760

5.  A 2-year longitudinal study of neuropsychological functioning, psychosocial adjustment and rehospitalisation in schizophrenia and major depression.

Authors:  Schaub Annette; Goerigk Stephan; Kim T Mueser; Hautzinger Martin; Roth Elisabeth; Goldmann Ulrich; Charypar Marketa; Engel Rolf; Möller Hans-Jürgen; Falkai Peter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-04-03       Impact factor: 5.270

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.